Zolasta 4 Mg Injection (Zoledronic Acid)
Price range: $213.99 through $530.85Required
| Pack Size | Price | Unit Price | Quantity | |
|---|---|---|---|---|
| 2 Injection | $213.99 | $107.00 / injection | ||
| 4 Injection | $384.34 | $96.09 / injection | ||
| 6 Injection | $530.85 | $88.48 / injection |
About Zolasta 4 Mg Injection (Zoledronic Acid)
Medicine information
- Active ingredient
- Zoledronic acid
- Indication
- Prevention of skeletal-related events, including pathological fractures, spinal cord compression, radiation or surgery to bone, and tumour-induced hypercalcaemia, in adults with advanced malignancies involving bone; treatment of tumour-induced hypercalcaemia in adults.
- Manufacturer
- Intas Pharmaceuticals Limited
- Packaging
- 1 x 5 mL vial
- Strength
- 4 mg
- Dosage form
- Concentrate for solution for infusion
- Route
- Intravenous infusion
Medicine overview
Zolasta 4 mg is a zoledronic acid medicine from the bisphosphonate class. Each 5 mL vial contains zoledronic acid monohydrate equivalent to 4 mg of anhydrous zoledronic acid and is supplied as a concentrate that must be diluted before intravenous infusion. It is used in adults with advanced cancers involving bone to help prevent skeletal complications and to treat high blood calcium caused by a tumour. Administration is performed by healthcare professionals experienced with intravenous bisphosphonates.
What it is used for
Zolasta is used in adults with advanced malignancies involving bone to reduce skeletal-related events such as pathological fractures, spinal cord compression, the need for radiation or surgery to bone, and tumour-induced hypercalcaemia. It is also indicated for treatment of tumour-induced hypercalcaemia, where cancer causes an abnormally high calcium level in the blood.
How it works
Zoledronic acid is a bisphosphonate that has a strong affinity for mineralised bone. It inhibits osteoclastic bone resorption, meaning it reduces the activity responsible for breaking down bone tissue. This slows excessive loss of bone mineral associated with cancers involving bone. By reducing abnormal bone breakdown, zoledronic acid can help lower the risk of skeletal complications and reduce calcium released from bone in tumour-induced hypercalcaemia.
How it is taken
Zolasta is administered by intravenous infusion by a healthcare professional. The concentrate must first be diluted in 100 mL of sterile 0.9% sodium chloride or 5% glucose solution and infused over no less than 15 minutes. It must not be mixed with calcium-containing or other divalent-cation-containing solutions such as lactated Ringer's solution. Patients should be adequately hydrated before and after administration. Dose selection and any reduction for renal impairment are determined by the treating clinician.
Important warnings
Do not use Zolasta in people with hypersensitivity to zoledronic acid, other bisphosphonates, or its excipients; breastfeeding is also contraindicated. Kidney impairment can occur, including renal failure, so renal function and serum creatinine require assessment, and severe renal impairment may make treatment unsuitable. Hypocalcaemia must be corrected before treatment, with calcium and vitamin D supplementation as appropriate. Osteonecrosis of the jaw has been reported; dental assessment and preventive dentistry should be considered before treatment in patients with risk factors, and new jaw pain, swelling, loose teeth, non-healing sores, or discharge should be reported promptly. Important interactions or additive risks can occur with nephrotoxic medicines, aminoglycosides, calcitonin, loop diuretics and other medicines that lower calcium. Zolasta should not be given concurrently with another zoledronic acid product or other bisphosphonates. Severe allergic reactions, atypical femoral fractures and severe musculoskeletal pain have also been reported.
Side effects and monitoring
Common effects include anaemia, headache, conjunctivitis, nausea, vomiting, decreased appetite, bone pain, muscle pain, joint pain, fever and flu-like symptoms such as fatigue, chills and malaise. Acute-phase reactions can occur within the first few days after infusion. Important serious or less common risks include kidney impairment or renal failure, severe hypocalcaemia, osteonecrosis of the jaw, severe allergic reactions, eye inflammation, atypical femoral fractures and cardiac or neurological effects secondary to severe hypocalcaemia. Serum creatinine should be assessed before doses, while calcium, phosphate and magnesium may require monitoring. Seek prompt medical attention for breathing difficulty or swelling suggestive of allergy, severe muscle spasms or seizures, markedly reduced urination, persistent jaw symptoms, or new unexplained thigh, hip or groin pain.
Pregnancy
Zolasta should not be used during pregnancy. Adequate human pregnancy data are unavailable, and reproductive toxicity has been observed in animal studies. Women of child-bearing potential should avoid becoming pregnant during treatment.
Breastfeeding
Zolasta is contraindicated during breastfeeding. It is not known whether zoledronic acid is excreted into human milk.
Food and drink
No product-specific food interaction was identified in the verified Zolasta prescribing information. Patients should be adequately hydrated before and after administration, while avoiding overhydration in people at risk of cardiac failure.
Storage
Store below 30°C. After dilution, the solution should preferably be used immediately. If immediate use is not possible, the verified product information states that storage would normally not exceed 24 hours at 2°C to 8°C unless dilution was performed under controlled and validated aseptic conditions.
Frequently asked questions
Why do I sometimes feel flu-like after a zoledronic acid infusion?
Zoledronic acid can cause an acute-phase reaction after an infusion. Symptoms can include fever, headache, muscle or joint pain, fatigue, chills, nausea and other flu-like symptoms, typically beginning within the first few days.
Do I need to drink extra water around my Zolasta infusion?
Adequate hydration is important before and after Zolasta administration. However, excessive hydration should be avoided in people at risk of heart failure, so hydration should follow the treating healthcare team's instructions.
Why does my kidney function need checking before Zolasta?
Zoledronic acid can impair kidney function and, rarely, has been associated with renal failure. Serum creatinine should therefore be assessed as directed before treatment doses, and dosing may need adjustment or treatment may need to be withheld when renal function deteriorates.
Why does my dentist need to know that I receive zoledronic acid?
Zoledronic acid has been associated with osteonecrosis of the jaw, a condition in which jawbone tissue becomes damaged. Dental assessment and preventive care may be recommended before treatment when risk factors are present, and jaw pain, swelling, loose teeth or non-healing mouth sores should be reported.
Can Zolasta lower my calcium level?
Yes. Hypocalcaemia can occur and can occasionally become severe. Calcium should be checked and existing hypocalcaemia corrected before treatment, with calcium and vitamin D supplementation used as clinically appropriate.
How long does a Zolasta infusion take?
The diluted Zolasta infusion must be administered over no less than 15 minutes. It is given intravenously by a healthcare professional rather than self-injected.
Can Zolasta be used during pregnancy or breastfeeding?
Zolasta should not be used during pregnancy and is contraindicated during breastfeeding according to the verified product information.
Will Cheap Generic Med shipping include tracking?
Under the standard international fulfilment model, tracked shipping is used and a tracking number should be provided after dispatch; carrier systems may take 24–72 hours to begin showing movement. Product-specific shipping availability for Zolasta has not been verified.
Sources
Medical information notice: This information does not replace advice from a qualified healthcare professional. Use prescription medicine only as directed by the prescriber and the approved product information.
| Active Ingredients | Zoledronic acid (4Mg) |
|---|---|
| Manufacturer | Intas Pharmaceuticals Ltd |
| Packaging | Qty |
| strength | 4mg |
| Delivery Time | 6 To 15 days |
Related products
Danogen 50 Mg (Danazol)
Duvadilan Retards 40 Mg (Isoxsuprine Hcl)
Femilon (0.02+0.15) Mg (Estradiol)
Reviews
There are no reviews yet.